XtalPi Advances Biologics Research with AI and Robotics

Author

Reads 4.8K

Scientists in a Laboratory
Credit: pexels.com, Scientists in a Laboratory

XtalPi is revolutionizing biologics research with the help of AI and robotics. By leveraging these cutting-edge technologies, XtalPi is able to accelerate the discovery and development of new biologics.

The company's innovative approach involves using AI to analyze complex data and identify patterns that can inform the design of new biologics. This allows researchers to focus on the most promising leads and streamline the development process.

XtalPi's AI-powered platform can process vast amounts of data in a fraction of the time it would take human researchers, enabling the company to test and refine its biologic candidates at an unprecedented pace. This has significant implications for the treatment of diseases and the development of new medicines.

About XtalPi

XtalPi is a cutting-edge technology company that's revolutionizing the way we think about pharmaceuticals.

Founded in 2016, XtalPi has been leading the charge in the field of artificial intelligence and machine learning.

The company's mission is to leverage AI and machine learning to accelerate the discovery of new medicines.

Credit: youtube.com, Empowering Discovery | XtalPi Corporate Video

XtalPi's innovative approach involves using AI to predict the optimal crystal form of a molecule, which can significantly improve the efficacy and safety of a drug.

This technology has the potential to save millions of lives and improve the quality of life for countless people around the world.

XtalPi's team of experts includes world-renowned scientists and engineers who are dedicated to making a meaningful impact in the pharmaceutical industry.

Partnerships and Collaborations

XtalPi has established itself as a leader in partnerships and collaborations, working with major pharmaceutical companies to accelerate drug discovery and development. This is evident in their collaboration with Eli Lilly and Company, where they will leverage XtalPi's AI and robotics platform to de novo design and deliver drug candidates for an undisclosed target.

XtalPi's collaboration with Eli Lilly and Company is just one example of their extensive partnerships. They also have a division called Ailux Biologics, which has partnered with UCB, a global biopharmaceutical company, to license their biologics AI platform, XtalFold.

XtalPi's AI and robotics platform has been licensed to multiple global pharmaceutical companies, including UCB, and has delivered highly impactful results in various projects, including antigen design, epitope identification, and affinity maturation.

Recommended read: Countryside Partnerships

UCB Partners with Ailux on Biologics AI Platform

Credit: youtube.com, Partnerships

UCB, a global biopharmaceutical company, has partnered with XtalPi, a global leader in AI drug discovery, on a license agreement for XtalFold, a biologics AI platform developed by Ailux Biologics, a division of XtalPi.

XtalFold is a proprietary AI-based software suite that provides rapid and accurate structural insights to accelerate biologics innovation across multiple phases. It utilizes sequence information alone to model the interaction between biomolecules, which forms the foundation of biotherapeutics like monoclonal antibodies.

In rigorous benchmark studies, XtalFold achieved state-of-the-art performance in terms of overall success rate and the quality of hard-to-model regions like the antibody-antigen interface. XtalFold has been licensed to multiple global pharmaceutical companies and has delivered highly impactful results in a variety of projects.

Ailux Biologics has established a state-of-the-art biologics discovery lab, a proprietary database purpose-built for AI (AtlaX), and a trio of AI platforms, including XtalFold, XenProT, and Xentient.

For more insights, see: Enterprise Value Multiples

Announces AI and Robotics Collaboration with Lilly

A Robotic Device
Credit: pexels.com, A Robotic Device

XtalPi, a pharmaceutical technology company, has announced a collaboration with Eli Lilly and Company worth up to $250 million in upfront and milestone payments. This collaboration will leverage XtalPi's AI capabilities and robotics platform to design and deliver drug candidates for an undisclosed target.

The collaboration will utilize XtalPi's ID4Inno small-molecule drug discovery platform, which combines AI, autonomous labs, and expert domain knowledge to generate and investigate a target-specific mega chemical space. This platform has already proven successful in empowering pharmaceutical innovation.

XtalPi's fleet of hundreds of autonomous robotic workstations can carry out precise and energy-efficient parallel chemical synthesis and assays 24/7. This high-quality real-world data generated with speed and at scale, combined with over 500 AI models and quantum physics algorithms, continuously enhance XtalPi's capability to predict and authenticate novel drug candidates with greatly accelerated timeframes and reduced experimental costs.

XtalPi has established itself as an industry leader in combining mutually informative AI "dry lab" algorithms with large-scale "wet lab" robotics. Its AI + robotics platform is supercharging the shift of pharmaceutical R&D from labor-intensive trial-and-error research to a computation and automation-intensive model.

XtalPi's CEO, Dr. Jian Ma, says, "With a closed loop of AI and quantum physics algorithms working in sync with the data factory of large-scale robotics experiments, XtalPi is uniquely equipped to tackle challenging novel targets."

Tencent Backed AI Startup Files for Hong Kong IPO

Credit: youtube.com, Tencent-Backed AI Drug Discovery Startup Xtalpi Files For Hong Kong IPO

Tencent backed AI startup Xtalpi has filed for an initial public offering in Hong Kong.

Xtalpi is a Shenzhen-based company that uses artificial intelligence to find chemical compounds that could be developed into new drugs.

The company has received significant funding, with $732 million raised since its inception in 2015, making it the largest AI drug discovery startup by total funding raised.

Xtalpi's last private fundraising was a $380 million Series D round in October 2021 that valued the company at about $2 billion.

The company has a strong team of experts, including three Chinese quantum physicists from the Massachusetts Institute of Technology who co-founded the company.

Xtalpi's AI technology combines quantum physics, cloud computing, and robotic automation to increase the efficiency and success rate of identifying novel drug compounds.

The company has recently expanded into discovering new chemical compounds for agricultural technology, cosmetics, and other applications.

Xtalpi has a diverse range of clients, including global leaders like Johnson & Johnson and Pfizer, as well as domestic players in the biotech industry.

Close-up view of ice crystals forming a textured pattern on a dark surface, suggesting winter.
Credit: pexels.com, Close-up view of ice crystals forming a textured pattern on a dark surface, suggesting winter.

The company's technology has attracted the interest of some of the world's biggest pharmaceutical companies, including Bayer, Eli Lilly, and Roche Holding.

Xtalpi's filings show that the company saw its net losses widen to 891 million yuan ($125.7 million) in the six months ended June from 581 million yuan in the same period in 2022.

The company reported a 86% jump in revenue to 80 million yuan during the same period.

Xtalpi generates income by providing drug discovery services to more than 100 biotech, pharmaceutical companies, and research institutions.

The use of AI in early-stage drug development could lead to an additional 50 novel therapies worth more than $50 billion in revenue over the next decade, according to Morgan Stanley.

Xtalpi's AI technology has already begun to yield results, with the company's XtalFold platform being licensed to multiple global pharmaceutical companies.

XtalFold is a proprietary AI-based software suite that provides rapid and accurate structural insights to accelerate biologics innovation.

The platform has achieved state-of-the-art performance in terms of overall success rate and the quality of hard-to-model regions like the antibody-antigen interface.

Close-up of a scientist using a syringe to handle chemicals in a laboratory setting.
Credit: pexels.com, Close-up of a scientist using a syringe to handle chemicals in a laboratory setting.

XtalFold has been used in a variety of projects, including antigen design, epitope identification, affinity maturation, pH-sensitivity engineering, and bispecifics design.

XtalPi is a global leader in AI drug discovery, with a team of experts dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors.

Patents and Funding

XtalPi has filed 1 patent, which is a significant milestone for the company.

The patent's title, "Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof", suggests a focus on developing new treatments for various diseases.

Here are some of the related topics associated with this patent:

  • Transcription factors
  • EC 2.7.1
  • Olfactory receptors
  • Clusters of differentiation
  • Oncology

Research Containing

Research containing XtalPi has been mentioned in 6 CB Insights research briefs, most recently on Oct 7, 2024.

CB Insights Intelligence Analysts have been tracking XtalPi's presence in their research.

XtalPi has been featured in 6 research briefs, showcasing its relevance in the industry.

Research containing XtalPi is a significant indicator of its importance in the field.

The mention of XtalPi in these research briefs highlights its growing presence in the industry.

On a similar theme: CB Insights

Patents

Credit: youtube.com, How to get your idea patented

XtalPi has filed a single patent, which is a relatively small portfolio compared to other companies. The patent's application date is January 25, 2022, and it's currently in the application stage.

The patent's title is "Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof." This title gives us a hint at the patent's focus on a specific area of research.

The patent's related topics include transcription factors, EC 2.7.1, olfactory receptors, clusters of differentiation, and oncology. These topics are all relevant to the life sciences industry, which is where XtalPi's expertise lies.

Here's a breakdown of the patent's status and dates:

XtalPi's patent filing is a significant development in the company's journey, and it's worth keeping an eye on their progress in this area.

Frequently Asked Questions

Who is the CEO of XtalPi?

Dr. Ma Jian is the CEO of XtalPi, a renowned expert in AI-driven drug discovery. He has received prestigious awards for his innovative work in the field.

Is XtalPi public?

XtalPi is publicly traded and its official SEC filings provide up-to-date information.

Abraham Lebsack

Lead Writer

Abraham Lebsack is a seasoned writer with a keen interest in finance and insurance. With a focus on educating readers, he has crafted informative articles on critical illness insurance, providing valuable insights and guidance for those navigating complex financial decisions. Abraham's expertise in the field of critical illness insurance has allowed him to develop comprehensive guides, breaking down intricate topics into accessible and actionable advice.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.